Key 12-week findings from the human trial include: 140% increase of GLP-1 on average 92% of participants lost weight , with an average of 11 pounds 92% saw a reduction in total body fat , with up to a 5.5% decrease 71% experienced a reduction in visceral fat , with up to a 27% decrease 100% of subjects who lost weight (92% of total subjects) maintained or saw an increase in muscle % , with up to a 2.7% increase No side effects were reported, including gastrointestinal issues* 85% agreed their food cravings decreased * 95% agreed their sugar cravings decreased * 96% agreed their portion sizes at each meal decreased * 85% agreed they now eat for health, not emotional reasons * 82% felt more in control of their relationship with food * * The clinical trial builds on successful in vitro research, which found that the MindBody GLP-1 System significantly increased GLP-1 production in L-cells by activating key genes
The clinic does not appear to fabricate patient outcomes, but the inconsistency between authentic patient photos and AI-looking promotional imagery is worth noting
In addition, CT exposes patients to ionizing radiation, and MRI has weight limits and requires longer scanning times
BLA planned for Q1 2027
That is redundant, not additive: you get amplified gastrointestinal side effects without a corresponding jump in benefit
Researchers should also distinguish eumelanin from generic darkening
